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Abstract
Vitamin D deficiency is a global issue, and despite all-year-round sunshine, it
is a big problem in the UAE. Obesity or overweight refers to an accumulation of
excessive fat that may harm health; so, it is considered a worldwide health concern.
The accurate measurement of vitamin D active forms is a problematic issue. The aim
of this study was to develop and validate a UHPLC-MS/MS method for the
determination of vitamin D metabolites and their epimers and then apply the new
method for the determination of vitamin D levels in the obese Emirati population. The
vitamin D epimers and other metabolites were determined by UHPLC-MS/MS system,
model 8060. The methods include the collection of blood samples from 729
individuals, divided into 277 baselines (vitamin D deficient volunteers), 277 followups (supplemented volunteers), and 175 healthy volunteers, extraction of vitamin D
and epimers from plasma samples, method development, and validation. The vitamin
D metabolites and their epimers have been separated by UHPLC-MS/MS instrument.
The method validation criteria were found in an acceptable range. Epimers of vitamin
D metabolites were found to cause an overestimation of 25OHD and give falsepositive results in the obese Emirati population. The results showed that baseline,
follow-up, and healthy volunteers are deficient in vitamin D's major metabolites.
UHPLC-MS/MS has superior selectivity. This new vitamin D blood test has been
successfully applied to estimate the vitamin D and epimer levels in the obese Emirati
population, and the results showed that the current vitamin D estimation methods are
overestimating the actual results. This new method will have far-reaching applications
in any future clinical studies.

Keywords: Vitamin D, vitamin D metabolites, epimers of vitamin D, UHPLCMS/MS, vitamin D blood test, obese Emirati population.
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)Title and Abstract (in Arabic

تحديد مستقلبات فيتامين د ومصاوغاتهم الصنوية في السكان اإلماراتيون البدناء
الملخص

يعد نقص فيتامين د مشكلة عالمية وعلى الرغم من سطوع الشمس طوال العام ،إال أنه
يمثل مشكلة كبيرة في اإلمارات العربية المتحدة .تشير السمنة أو زيادة الوزن إلى تراكم الدهون
الزائدة التي قد تضر بالصحة؛ لذلك ،يعتبر مصدر قلق صحي عالمي .يعتبرالقياس الدقيق ألشكال
فيتامين د النشطة قضية إشكالية .الهدف من هذه الدراسة هو تطوير والتحقق من صحة طريقة
) (UHPLC-MS/MSلتحديد مستقلبات فيتامين د ومصاوغاتهم الصنوية ثم تطبيق الطريقة
الجديدة لتحديد مستويات فيتامين د في السكان اإلماراتيين البدناء .تم قياس كمية المصاوغات
الصنوية لفيتامين د والمستقلبات األخرى بواسطة نظام ) ،(UHPLC-MS/MSنموذج .8060
تشمل الطرق جمع عينات الدم من  729فردًا (منهم  277فردا ً من المتطوعون اللذين يعانون من
نقص فيتامين د ،و 277فردا ً من المتطوعون المكملون بالمكمالت الغذائية ،و  175فردًا من
المتطوعون األصحاء) ،واستخراج فيتامين (د) و المصاوغات الصنوية من عينات البالزما،
وتطوير هذه الطريقة والتحقق من صحتها .تم فصل مستقلبات فيتامين د ومصاوغاتهم الصنوية
بواسطة تقنية ) .(UHPLC-MS/MSوكانت معايير التحقق من صحة الطريقة في نطاق مقبول.
تقديرا مفر ً
طا لـ 25OHDوتعطي نتائج
ۇجد أن المصاوغات الصنوية لمستقلبات فيتامين د تسبب
ً
ِ
إيجابية خاطئة في السكان اإلماراتيون البدناء .أوضحت النتائج أن المتطوعون الذين يعانون من
نقص فيتامين د ،والمتطوعون المكملون بالمكمالت الغذائية ،والمتطوعون األصحاء يعانون من
نقص في المستقلبات الرئيسية لفيتامين د .يتميز ) (UHPLC-MS/MSبانتقائية فائقة .تم تطبيق
اختبار الدم الجديد لفيتامين (د) بنجاح لتقدير مستويات فيتامين (د) و المصاوغ الصنوي في السكان
اإلماراتيون البدناء ،وأظهرت النتائج أن طرق فيتامين د الحالية تبالغ في تقدير النتائج الفعلية.
سيكون لهذه الطريقة الجديدة تطبيقات بعيدة المدى في أي دراسات سريرية مستقبلية.

مفاهيم البحث الرئيسية :فيتامين د ،مستقلبات فيتامين د ،المصاوغات الصنوية لفيتامين د،
 ،UHPLC-MS/MSفحص فيتامين د في الدم ،السكان اإلماراتيون البدناء.
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Chapter 1: Introduction
1.1 Overview
Obesity or overweight refers to an accumulation of excessive fat that may harm
health; so, it is considered a worldwide health concern [1]. Obesity is associated with
developing different diseases, including hypertension, cardiovascular disease, diabetes
mellitus, and cancer; therefore, it will increase the mortality rate and morbidity. Also,
obesity could lead to social discrimination and less physical activity [2, 3]. Genetics
and eating behavior are factors leading to obese development [4, 5]. Various studies
confirmed a relationship between vitamin D and obesity; however, the causal
relationship has not yet been elucidated [6]. The possible mechanism for the inverse
relationship between Body Mass Index (BMI) and vitamin D serum levels is the
volumetric dilution of vitamin D. Although the vitamin D quantity in lean and obese
people are similar, the vitamin D concentration in obese people is lower due to the
dilution of vitamin D in an immense volume [7]. However, if low 25-hydroxyvitaminD (25OHD) levels in obese subjects are caused by volumetric dilution, this means that
25OHD serum levels could be increased upon weight loss. Nevertheless, studies about
weight loss illustrate inconsistent results. For instance, Mason et al. [8] reported an
insignificant increase of 25OHD serum levels in a large number of obese and
overweight postmenopausal volunteers who undergo a diet and exercise plan for a
weight loss. Namely, there was an increase in 25OHD of 2.1, 2.7, 3.3, and 7.7 ng/ml
for participants who loss in their weight <5%, 5-9.9%, 10-14.9% and >15%,
respectively [8]. One study found that vitamin D supplementation increases the
25OHD serum concentration in lean subjects more than in obese subjects [9].
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According to Drincic et al. [10], the adjustment of vitamin D supplementation has to
be conducted in obese subjects, which could eliminate the difference in increasing the
25OHD serum level upon supplementation between lean and obese subjects . Another
study reported an excess amount of body fat could deactivate an essential hormonal
pathway for skeletal health. For instance, the pathways for the synthesis of active
metabolites of vitamin D could be inhibited by a leptin hormone derived from
adipocytes [11].
Vitamin D is a prohormone; it is fat-soluble and derived from cholesterol.
Vitamin D is obtained from two sources: the first source is sunlight or artificial
ultraviolet-B (UV-B) exposure and the second source is from food like fish, eggs, milk,
and cereals, or vitamin D supplements [12, 13]. Exposure to UVB is a major source of
vitamin D, and limited exposure to UVB radiation can negatively impact vitamin D
synthesis in the skin [14]. It is also known that people with darker skin require more
prolonged sun exposure compared to light-skinned people. For example, the dark skin
has more amounts of melanin pigment compared to the light skin, which causes in
reducing the ability of skin to produce vitamin D from sunlight [15]. In some countries
in the world, despite the year-round sunlight, there is a high prevalence of vitamin D
deficiency [14, 16, 17]. Vitamin D deficiency is correlated with the development of
many diseases, including rickets, osteomalacia, arthritis, diabetes, dementia,
Parkinson’s, Alzheimer’s, and cardiovascular diseases [18]. Furthermore, vitamin D
deficiency is also associated with aging, obesity, skeletal muscle weaknesses, and
metabolic syndrome diseases. The role of vitamin D epimers in disease onset and
progression is not clearly understood, but it is known that epimers have a potent role
as compared to their corresponding non-epimeric forms [12, 14, 19-22].
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There are two primary metabolites of vitamin D, vitamin D3 and vitamin D2,
which are collectively known as vitamin D [18, 23]. Vitamin D3 is formed from its
precursor 7-dehydrocholesterol in the skin by ultraviolet B light (medium wavelength,
290-315 nm). In the first step, 7-dehydrocholesterol is converted to pre-vitamin D3
which is followed by conversion of pre-vitamin D3 to vitamin D3, as shown in Figure
1 [24-26]. The second step is governed by the conversion of vitamin D3 to 25OHD3
in the liver via the 25-hydroxylase (CYP2R1) enzyme, as shown in Figure 1 [27]. In
the liver, the 3-epimerase enzyme also converts 25OHD3 to 3-epi-25OHD3. 25OHD3
and 3-epi-25OHD3 are converted into 1α,25(OH)2D3 in the kidneys via the action of
the enzyme 1α-hydroxylase (CYP27B1), as shown in Figure 1 [28, 29]; 3-epimerase
enzymes also convert 25OHD3 into 3-epi-1α,25(OH)2D3. Moreover, 3-epi-25OHD3
also becomes converted into 3-epi-1α,25(OH)2D3 in the kidneys. Likewise,
1α,25(OH)2D3 is converted into 3-epi-1α,25(OH)2D3 via the action of the epimerase
enzyme. Sometimes, however, 25OHD3 and 1α,25(OH)2D3 undergo further oxidation
using enzyme epimerases and are converted into epimeric forms like 3-epi-25OHD3,
3-epi-1α,25(OH)2D3, and 3-epi-24R,25(OH)2D3.
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Figure 1: Sources and metabolism of vitamin D. Sunshine activate a chemical reaction in the
plasma membrane of dermal fibroblasts and epidermal keratinocytes in the skin, producing an
unstable form, 7-dehydrocholesterol, which forms pre-vitamin D3 and, upon thermal
isomerization, produces a stable vitamin D3 form. Dietary sources are another source of
vitamin D3 and D2. Hydroxylation of vitamin D3 occurs in the liver using enzyme CYP2R1,
mainly forming 25OHD3. In the kidney, 25OHD3 undergoes further hydroxylation at the C1α or C-24 positions. The CYP27B1 enzyme is responsible for C-1α hydroxylation, while
CYP24A1 is responsible for C-24 hydroxylation. CYP24A1 can inactivate 25OHD3 to
produce 24R,25(OH)2D3, while 3-epimerase enzyme could inactivate the major metabolites (
25OHD3, 24R,25(OH)2D3, and 1α,25(OH)2D3 ) in the epimerization process by changing the
orientation of only one group [30].
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Recently it was found that C3-epimers of vitamin D may have an important
role to play in the body. The exact source of C3-epimers is not known but it was found
that oral supplementation of vitamin D can cause increased production of epimers in
mice but not in humans, the 25OHD3 levels and its epimer were determined in this
study by using LC-MS/MS [31]. Moreover, it is known that all major vitamin D
metabolites can be epimerized at the C3 position, with higher amounts in infants [32].
Furthermore, mothers and newborns are known to have high levels of C3-epimers [33].
Recent genetic models also show that the genetic determinants and potential factors of
C3-epimers differ from those of non-C3-epimers [34]. It is also of importance that the
C3-epimers can cause an overestimation of vitamin D status in routine laboratory tests
[18]. However, very few labs in the world take into account that measurements can be
misleading due to overlapping C3-epimers and that these co-eluting C3-epimers can
be separated from vitamin D metabolites using Liquid Chromatography-Tandem Mass
Spectrometry (LC-MS/MS) techniques [35]. Studies have shown that routine vitamin
D blood tests for healthy adults are not significantly affected by epimeric interference
using LC-MS/MS assays [36]. However, in the present study, the baseline (vitamin D
deficient volunteers) and follow-up samples (supplemented volunteers) were added
and compared with healthy samples. The vitamin D supplements could increase the
epimer levels more than the major form of vitamin D; therefore, the epimers will
significantly affect routine vitamin D blood tests. Moreover, the routine vitamin D
blood tests are not affected by epimers when LC-MS/MS techniques are employed in
vitamin D blood tests due to the separation of vitamin D epimers from major forms by
these techniques.
In neonatal human keratinocytes, Reddy et al. [37] has concluded that 3-epi1α,25(OH)2D3 is metabolized through the C-24 oxidation pathway to produce three
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polar compounds: 3-epi-1α,24,25(OH)3D3, 3-epi-24-oxo-1α,25(OH)2D3, and 3-epi24-oxo-1α,23(S),25(OH)3D3, while C-23 oxidation of 3-epi-1α,25(OH)2D3 produces
3-epi-1α,23(S),25(OH)3D3, as shown in Figure 2 [24, 37]. The C-24 oxidation
pathway is catalyzed by the 1α,25(OH)2D3-24-hydroxylase (CYP24) enzyme. The
biological activity of 3-epi-1α,25(OH)2D3 and its metabolites have not yet been
identified [37].
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Figure 2: The C-23 and C-24 oxidation pathways for 1α,25(OH)2D3 and its epimer [30].
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In the epimerization pathway, for example, the intermediate metabolites of
major vitamin D precursors are converted to epimers, which undergo the same
hydroxylation and oxidation events by the same enzymes when compared to the
standard metabolic pathway, which also subsequently leads to the production of
epimers like 3-epi-25OHD3, 3-epi-1α,25(OH)2D3, and 3-epi-24(R),25(OH)2D3 [24,
38-42].
To write this chapter, some electronic databases were searched, including
NCBI PubMed, Google Scholar, SciFinder, and ScienceDirect, for English language
articles. This was done using keywords such as epimers of vitamin D, C3-epimers,
metabolism of vitamin D epimers, epimerization pathway for standard metabolism of
vitamin D, the function of the epimer of 1α,25(OH)2D, detection and quantitative
analysis of vitamin D epimers, and the effects of epimers on routine analysis of total
circulating vitamin D (25OHD) and its determination in serum. Due to an increased
interest in epimers of vitamin D and their possible relationship with health and disease,
it was decided to carry out this subjective literature survey.
1.2 C3-Epimerization of Vitamin D
The epimers of 25OHD3 and 1α,25(OH)2D3 were also found in rats when given
pharmacological doses of 25OHD3 and 1α,25(OH)2D3 supplements over a period of
time [38, 42]. The epimerase enzyme (25OHD3-3-epimerase) is known to be
responsible for the epimerization of 25OHD3 at the C3 location in the endoplasmic
reticulum of liver, bone, and skin cells. However, the gene responsible for encoding
the epimerization enzyme has not yet been identified [28]. NADPH is also utilized as
a cofactor for the action of 25OHD3-3-epimerase in the microsomes of osteoblastic
UMR-106 cells (these are transplantable rat osteogenic sarcoma cell lines, and these
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cell lines are responsive to PTH, prostaglandins, and bone-resorbing steroids like
vitamin D). Furthermore, epimerase enzymes can carry out the epimerization process
of 1α,25(OH)2D3, and 24(R),25(OH)2D3 but not at the same rate as 25OHD3.
Moreover, the observation shows that this process is irreversible [28, 43].
It is known that the epimerization process for 25OHD3, 24(R),25(OH)2D3, and
1α,25(OH)2D3 occurs in some specific culture cells, including quiescent human colon
adenocarcinoma cells (Caco-2 colon carcinoma cells), human hepatoblastoma cells
(HepG2 cells), human osteosarcoma (MG-63) [44], bovine parathyroid cells [41], and
porcine kidney cells (LLC-PK1) [44]. Vitamin D supplementation has recently
become common, and more studies are recommended to determine the origin of
epimers, either produced by exogenous sources or when metabolized endogenously;
additionally, it will be beneficial to understand the nature and properties of the
enzymes or tissues responsible for the epimerization process to obtain an in-depth
understanding of epimers [24]. A recent study reported that 25OHD3, 1α,25(OH)2D3,
and 24,25(OH)2D3 can be respectively epimerized into 3-epi-25OHD3, 3-epi1α,25(OH)2D3, and 3-epi-24,25(OH)2D3 in many different cell cultures types, such as
LLC-PK1, Caco-2, UMR-106, Hep-G2, and MG-63 cells, but at different proportions,
which were determined and quantified using 1H NMR spectroscopy and LC-MS
techniques. For example, the C3 epimerization of 25OHD3 and 1α,25(OH)2D3 mostly
occurs in equivalent amounts in UMR-106, LLC-PK1, and Caco-2. However,
compared to other epimers, Hep-G2 and MG-63 cells mostly produce 3-epi-25OHD3,
while 3-epi-24,25(OH)2D3 is the least produced of the epimers [38].
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1.3 Role of Epimers in Calcium, Phosphorus and PTH Homeostasis Compared
to Parent Metabolites
As mentioned earlier, 1α,25(OH)2D3 is considered to be the most effective
vitamin form; its principal function is to increase the amount of calcium and phosphate
to normal levels in plasma, and it is also required to optimize bone health. Moreover,
1α,25(OH)2D3 suppresses parathyroid hormones (PTH) by binding to VDR, thereby
inhibiting gene expression and cell proliferation and causing the levels of calcium to
increase [13, 24]. It is known that 3-epi-1α,25(OH)2D3 has fewer calcemic effects than
non-epimeric forms of vitamin D [45] but, compared to other epimeric forms of
vitamin D, it is the most efficient [38]. It was also recently discovered that 3-epi25OHD3 and its calcemic effects are higher than those of 3-epi-24,25(OH)2D3 [38].
3-epi-25OHD3 and 3-epi-1α,25(OH)2D3 have less affinity toward DBP and even
lower affinity for VDR compared to primary metabolites 25OHD3 and 1α,25(OH)2D3,
which will lead to a reduction in the ability of epimers to induce calcium transport, as
well as a much-reduced gene expression in the human colonic carcinoma cell line,
Caco-2 [46, 47]. For example, the bone gamma-carboxy glutamic acid-containing
protein (BGLAP, osteocalcin) and the CYP24 gene are activated by 3-epi1α,25(OH)2D3 but at a much lower rate than 1α,25(OH)2D3 [24, 38, 48]. Furthermore,
3-epi-1α,25(OH)2D3 has less control on the antiproliferation and differentiation of
cells compared to 1α,25(OH)2D3, such as HL-60 promyelocytic leukemia cells,
keratinocytes, and rat UMR-106 osteosarcoma cells [24, 28]. Moreover, parathyroid
hormone secretions can be suppressed by 3-epi-1α,25(OH)2D3 in bovine parathyroid
cells with almost the same potency as its parent metabolite [41]. Moreover, some
biological studies conducted on pulmonary alveolar type II cells show that 3-epi1α,25(OH)2D3 can boost the synthesis of surfactant phospholipids and activate gene
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expression to yield an increase in the synthesis of surfactant protein-B (SP-B) [24, 45].
Also, 3-epi-1α,25(OH)2D3 has greater metabolic stability than 1α,25(OH)2D3 [24,
49]. For example, the rate of metabolism (side-chain oxidation) by CYP24A1 in
human keratinocytes for 3-epi-1α,25(OH)2D3 is less than that of its parent metabolite
[28, 50, 51]. The biological activity of 3-epi-25OHD in humans has not yet been
identified [52]. The biological activity of the C3-epimer has been demonstrated in most
in vitro models; however, the physiological functions of the C3-epimer remain unclear
despite having been studied using in vivo models [24, 46, 53].
The C3-epimer has been shown to possess some calcemic and non-calcemic
regulatory effects compared to its non-epimeric form. Compared to the respective
25OHD3 and 1α,25(OH)2D3 forms, the C3-epimers (3-epi-25OHD3 and 3-epi1α,25(OH)2D3) bind to DBP at about 36-46% and VDR at 2-3%. However, 3-epi1α,25(OH)2D3 induces BLGP (osteocalcin) VDR-binding downstream at only ~15%,
as well as CYP24 gene expression, compared to 1α,25(OH)2D3. Similarly, 3-epi1α,25(OH)2D3 has been shown to possess more differentiation or antiproliferative
activities (approximately 30% and 10%) than the non-epimeric compound. It is also
known that the parathyroid hormone is suppressed by 3-epi-1α,25(OH)2D3 and that
epimers are responsible for inducing phospholipid synthesis in pulmonary alveolar
type II cells in comparable amounts to the non-epimeric form. Moreover, 3-epi1α,25(OH)2D3 has been proposed to have higher metabolic stability than
1α,25(OH)2D3, despite having non-equivalent VDR binding [24]. Due to its weak
interactions with VDR, the vitamin D epimer will remain in a free form, which might
affect bodily function and give false-positive results using normal measurement
methods.
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1.4 The Potency of Epimerization in Microsomal Fractions
Bone cells (UMR-106) were used to collect subcellular fractions (homogenate,
nuclei, mitochondria, and microsome fractions), and when 1α,25(OH)2D3 was
incubated with these fractions, the potency of epimerization was observed to be the
highest in microsomal fractions compared to others. Moreover, when comparing the
epimerization activity of liver cells (HUH-7, HepG2), colon cells (Caco2), and bone
cells (MG-63, UMR-106), it was found that the highest proportions of epimerization
were found in the microsomal fractions for UMR-106 cells [43]. Recently, it was found
that 3-epi-24,25(OH)2D3 could be formed from the epimerization of 24,25(OH)2D3,
and this reaction is catalyzed by 3α-HSD and β-HSD (studied in the presence of
testosterone in Pseudomonas bacteria), where the nicotinamide adenine dinucleotide
(NAD) and nicotinamide adenine dinucleotide phosphate (NADPH) act as coenzymes
in the reaction [54]. It was also found that this reaction could be modified for nonepimeric forms, like 24,25(OH)2D3, which could also be catalyzed by the same
enzymes (3α-HSD and β-HSD) [43]. Furthermore, it was noted that the cytosol is the
region where β-HSD and α-HSD could be most efficient [55-57], and it was reported
that 3α-HSD and β-HSD enzymes could also be responsible for epimerization in
microsomal fractions but in very small proportions [43].
1.5 The Role of DBP, VDR, and Genetics in Epimerization
The differences in the molecular structures of 25OHD3 and its epimer lie in the
configuration of only one functional group at a specific carbon (C-3), whereby the
hydroxyl groups in 3-epi-25OHD3 and 3-epi-1α,25(OH)2D3 have different
orientations in space compared to 25OHD3 and 1α,25(OH)2D3, respectively (C-3α vs.
C-3β) [28, 35]. The vitamin D-binding protein (DBP) and vitamin D receptor (VDR)
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are two proteins that are central to the metabolism and mechanism of action related to
the circulation of the vitamin D metabolite, 1α,25(OH)2D3 [28, 58]. The vitamin Dbinding protein (DBP) transports vitamin D metabolites through blood vessels toward
different tissues, and these metabolites rarely circulate in free form. The liver is one of
the organs that are responsible for producing DBP. Liver, intestinal, or renal diseases
will lead to a decrease in DBP, which will cause a reduction in vitamin D metabolites
and produced epimers. However, this does not mean that people with low DBP are
deficient in vitamin D as the free form of vitamin D could be within the normal range
[58]. When active 1α,25(OH)2D3 reaches a target cell, it is released from the DBP.
After that, it is attached to vitamin D receptors on the cells, and the target cells will
uptake this free active metabolite 1α,25(OH)2D3 inside the cell; the metabolite will
then either be rapidly metabolized by the 1α,25(OH)2D-24-hydroxylase (CYP24A1)
enzyme through the C-24/23 oxidation pathway leading to the formation of other
metabolites, or it will be re-attached to VDR [24, 28, 58]. The VDR will then go
through conformational changes within the nucleus that will allow other
transcriptional factors to combine with 1α,25(OH)2D3, which will ultimately influence
gene transcription. To initiate gene expression, the active vitamin D–VDR complex
must interact with retinoid X receptor (RXR), which recognizes the selective or
promoter sites of DNA and transcription begins; however, transcriptional activity and
VDR binding affinity were found to be weaker for 3-epi-1α,25(OH)2D3 than for
1α,25(OH)2D3. Therefore, it was concluded that 3-epi-1α,25(OH)2D3 performs gene
regulation in the same manner as its non-epimeric analogue, but less efficiently. It was
also concluded that epimers will have limited binding capabilities to DBP and VDR
which will, in turn, influence gene transcription. This difference in orientation (C-3α
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vs. C-3β) likely makes this affinity and potency differ between 1α,25(OH)2D3 and its
epimer, as shown in Figure 3 [38, 58, 59].

Figure 3: Comparison between 1α,25(OH)2D3 and 3-epi-1α,25(OH)2D3 in terms of gene
regulation. (A) When 1α,25(OH)2D3 is released from DBP, it will cross the cell membrane
and enter the target cell to bind with VDR. The 1α,25(OH)2D3–VDR complex undergoes
translocation to the nucleus and performs conformational changes in order to link with other
transcriptional factors and heterodimerize with RXR. After that, the 1α,25(OH)2D3–VDR–
RXR complex binds to the vitamin D response element (VDRE); then, the transcription of
RNA begins for the specific genes that are then expressed as different proteins responsible for
vitamin D homeostasis. (B) We assume that 3-epi-1α,25(OH)2D3 will carry out the same
function but at a slower rate. The 3-epi-1α,25(OH)2D3 complex could likely perform the same
gene regulation as its non-epimeric forms but at a lower rate [30].
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For example, VDR binds with an active vitamin D metabolite to induce
genomic action which inhibits growth in renal osteodystrophy, breast, or prostate
primary tumor cells, lymphomas, psoriasis, or in autoimmune diseases and
osteoporosis [58, 60]. However, the role of epimers in these contexts remains unclear.
A recent study hypothesized that genetic polymorphisms in the vitamin D-related gene
pathway cause variation in C3-epimer levels. In this study, candidate single-nucleotide
polymorphisms (SNPs) with regard to C3-epimer levels were investigated.
Interestingly, it was noted that participants carrying a minor T allele exhibited a
tendency to increase their levels of C3-epimer, while those carrying a minor G allele
tended to produce a decreased level of both non-C3-epimers and C3-epimers [34].
1.6 Vitamin D Epimer Levels in Humans
The source of vitamin D epimers, whether from endogenous metabolism, diet,
or supplementation, remains unclear [61]. Previously, it was found that, if
endogenously synthesized, the immaturity of renal and hepatic tissues could be
responsible for epimerization of the major metabolites of vitamin D. Subsequently, a
new study has found that there is no diﬀerence in the epimer levels between healthy
adults and adults with compromised liver function. For example, these studies want to
find if the epimerization process could take place either in the liver or kidney. They
discovered no difference in epimer levels between healthy adults who have intact liver
and adults who have compromised liver; therefore, the epimerization could take place
in the kidney or even in the skin before the vitamin D being further hydroxylated [32,
46]. Previously, it was found that supplements of vitamin D3 are not a possible source
of epimerization and, therefore, do not constitute a potential cause [62]. However, a
recent study has shown that epimer levels are proportionally higher with oral
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supplementation of vitamin D compared to the ultraviolet irradiation of mice skin. This
was not the case in humans; for instance, the epimer levels could be increased either
by vitamin D supplements or by the ultraviolet irradiation of human skin or both;
however, the mechanism was not identified yet [31]. A recent study where oral
supplementation was compared with sunshine exposure in an animal model vs. human
model found that the total levels of epimers (3-epi-25OHD3) were higher with oral
supplementation than with sunlight exposure in an animal model while in human
model, oral supplementation and sunlight exposure were increased the levels of
epimers. Further experiments showed that sun exposure causes a decline in epimer
levels in the animal model; however, the mechanism for this process was not
identified. Nonetheless, it was noted that several variables might be responsible for the
breakdown or production of epimers. It was found that CYP2R1 gene expression in
mice livers is greater with vitamin D supplements compared to sunshine irradiated
mice [31].
It is not known whether the epimerization process happens before or after
hydroxylation. The epimerization process takes place in various other tissue types,
including kidney, colon, liver, and bone cells, and the degree of epimerization is
diﬀerent between these tissues [31, 38]. Epimerization could also occur in the skin and
lead to the epimerization of pre-vitamin D3, and therefore, the expression of 25hydroxylase (CYP2R1) will be less eﬃcient, thus leading to a decrease in 3-epi25OHD3 production [31]. One study found a considerable increase in the expression
of the CYP24A1 gene in the renal cells of mice exposed to sunlight (UV-irradiated)
compared to those with vitamin D supplements [63]. When the activity of CYP24A1
enzyme increases, the catabolism of 25OHD3, 1α,25(OH)2D3, and the corresponding
epimeric forms increases. Thus, these epimers could also be decreased by an increase
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in the activity of the CYP24A1 enzyme [31]. Recently, it was found that vitamins D3
and D2 can also be hydroxylated by the CYP11A1 enzyme, which leads to the
production of a few new vitamin D metabolites, 20, 22(OH)2D3 or D2 and 20OHD3
or D2. Thus, it was found that CYP27A1, CYP27B1, and CYP24A1 can also carry out
further hydroxylation [64, 65]. The activity of the CYP11A1 enzyme has been
observed in epidermal keratinocytes, where 20, 22(OH)2D3 and 22OHD3 were formed
in higher proportions [66]. If true, CYP11A1 may be activated by UVB exposure, and
the availability of the vitamin D3 substrate for classical hydroxylation to form
25OHD3 and its epimer could be lower in the absence of sunlight [31].
Vitamin D metabolism is aﬀected by diﬀerent characteristics of humans and
mice. The first characteristic is the structure of the skin. For instance, the melanocytes
in human skin are present at the basal layer of the epidermis, while in mice,
melanocytes are present in the hair follicle and the dermis. Mice also have a higher
pelage density compared to humans; furthermore, the permeability and fragility of the
stratum corneum are higher for rodents than for humans [67-69]. Moreover, humans
are diurnal animals, while mice are nocturnal animals, which means that mice depend
mostly on vitamin D supplements for their vitamin D stores, while humans rely on
UVB exposure to synthesize vitamin D [31]. Singh et al. [32] also determined the C3epimer by using LC-MS/MS, though not in all ages—only among those less than one
year old .
1.7 C-3 Epimer Levels in Newborn and Adults
The epimer for children (<1 year) accounted for 8.7–61.1% of overall 25OHD.
It was also hypothesized that the formation of epimers might depend on the maturity
of the liver because the number of epimers is reduced in the blood of the infants
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compared to adults [32]. Moreover, van den Ouweland et al. [70] established that the
percentage of the C3-epimer of 25OHD was up to 60% higher in infants compared to
only 22% in adults . Moreover, Studies noticed that adult pregnant women have higher
concentrations of epimers (80% detectable epimers) compared to blood donors (43%
detectable epimers). In this study, 3-epi-25OHD3 was found in all pregnant women
and their cord blood, comprising 6.0% and 7.8% of 25OHD3, respectively. When the
epimer was not accounted for in vitamin D estimations, 38% of women and 80% of
newborns were classified as having an insuﬃcient concentration (<75 nmol/L).
However, with the epimer included in the estimation of insuﬃciency, 33% of women
and 73% of neonates were found to have suﬃcient levels of vitamin D. It is assumed
that a high use of dietary supplements in women could have contributed to the
formation of high levels of epimers in both maternal and cord blood [33, 71, 72].
Vitamin D deficiency is generally regarded as 30 nmol/L or lower, while
suﬃcient vitamin D levels for healthy people range between 40 and 80 nmol/L [36].
The range of absolute epimer concentrations for the infant population is 0–230 nmol/L,
with an average of 18.2 nmol/L, while the range for epimer concentration in the adult
population is around 0–22.5 nmol/L, with a mean value of 4.3 nmol/L. It is concluded
that as the infants grow older, their epimers levels start decreasing. These levels remain
approximately constant during their entire adult life. The percentage of C3-epimers of
the total 25OHD3 ranged between 0% and 61.1% for infants and 0% and 47% for
adults, with an average of 21.4% for infants and 5.9% for adults, respectively [24, 73,
74]. According to Chailurkit et al. [75], the concentration of vitamin D epimer was
greater in males than in females. According to Keevil et al. [74], insuﬃcient levels of
vitamin D are estimated as below 50 nmol/L, while the epimer concentration could be
equal to 2.5 nmol/L. Therefore, clinical interpretation is not hugely aﬀected in adults
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or children [24, 74]. Nonetheless, when the epimers were quantified, a percentage of
infants and adults were misclassified as suﬃcient, with values determined at 9% and
3%, respectively [76]. Keevil et al. [74], concluded that the epimer for 25OHD3
performs a significant role in clinical applications; however, it could have a minimal
eﬀect on routine LC–MS/MS measurements. It was also shown that high levels of
epimers can be found in pregnant women and their newborns, and it was suggested
that the role of epimers in characterizing vitamin D status in pregnancy and infancy is
imperative [33]. Others suggest that clinicians should determine the C3-epimer during
routine analysis, especially among pediatric and infant populations [24]. The
production of vitamin D epimer in humans is variable [63]. Moreover, levels of 3-epi25OHD3 production could be related to gender, age, and living areas (rural areas vs.
urban areas) [74].
1.8 Techniques for Measurement of Vitamin D Metabolites and Epimers
The epimers of vitamin D have been investigated in many studies [18, 35, 62,
73, 74, 76-80]. Immunoassay techniques have diﬃculty separating the D2 form of
vitamin D from D3 forms, and these techniques can only give the total 25OHD value
in a measurement. For example, these techniques are based on the binding between an
antigen (analyte) and its antibody. The antibodies for 25OHD3, 25OHD2, and their
epimers are the same [35, 81-84]. The diﬀerentiation between 25OHD2 and 25OHD3
in most immunoassay techniques is not possible, as these techniques consider both as
one entity [85]. Current LC–MS/MS techniques can separate D2 forms from D3 forms,
but they have diﬃculty in separating the interference caused by the epimeric and
isobaric metabolites. In some vitamin D LC–MS/MS with electrospray ionization
techniques, the ionization potency of 3-epi-25OHD3 is higher than that of 25OHD3,
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which will lead to an overestimation of 3-epi-25OHD3 if it is not separated from its
non-epimeric components [28]. These techniques lack specificity, which aﬀects the
estimation of major vitamin D metabolites and will lead to false-positive results [86,
87]. Therefore, it is essential to separate epimers from the primary active forms of
vitamin D that can overlap and compromise the accuracy of the method [18]. In the
past 10 years, innovations in analytical techniques have had the beneficial ability to
separate vitamin D forms from co-eluting epimers, and there are many published
methods, which can separate the epimers of vitamin D, as shown in Table 1 [18, 35,
61]. The separation of epimers from vitamin D metabolites is considered a challenge
as these epimers have the same mass-to-charge ratios as non-epimeric metabolites.
Further, mass diﬀerentiation is not possible using most standard LC–MS techniques
as these epimers require chromatographic separation [24, 88].
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Table 1: Methods used for separation of vitamin D epimer in the past 10 years.

Year

2010
2011

2012

2013
2014
2015

2016

2017

2018

2019

MS/MS
instrumentionization
mode

Mobile Phase -column

Isocratic mobile phase (34% H2O +
66% methanol) – Zorbax SB CN
column
API
methanol/H2O/formic acid -Zorbax
4000/APCI
cyanopropyl HPLC column.
acetonitrile +0.3% formic
acid/ammonium acetate (2 mM) +
API-3000/ESI
0.1% formic acid – Ultrason ESOVM chiral column +Zorbax SBC18 column
API 4000
H2O/Methanol - Phenomenex
QTRAP/APCI
Kinetex PFP column
Waters Xevo
H2O/Methanol – BEH - Phenyl
TQ-S/ESI
UPLC column
0.1% formic acid in water/0.1%
API 5500
formic acid in methanol – waters
QTRAP/ESI
pentafluorophenyl (PFP) column
ammonium formate in
Agilent
H2O/ammonium formate in MeOH
6410/ESI
–Pursuit PFP +Poroshell 120 ECC18 column
0.1% formic acid in water,
API 4000/ESI
methanol - Raptor FluoroPhenyl
column
3 mM ammonium formate in H2O/
Agilent
3 mM-ammonium formate in
6460/ESI
methanol – PFP column
0.1% formic acid in water/0.1%
Shimadzu
formic acid in acetonitrile –
8050/ESI
Kinetex F5 column
API
4000/APCI

Run
Time
(min)

Reference

40

[89]

14

[90]

20

[91]

7.0

[62]

<5

[92]

10

[93]

28

[94]

7

[95]

35

[96]

8

[80]

It is known that LC–MS/MS is the most recommended method for analysis of
vitamin D, especially in young infants, due to its ability to detect and quantify epimeric
and non-epimeric metabolites separately in plasma [28, 97]. One study illustrated that
ultra-performance supercritical fluid chromatography-tandem mass spectrometry
(UPSFC–MS/MS) could be used as an alternative technique to Ultra-Highperformance Liquid Chromatography-Tandem Mass Spectrometry (UHPLC–MS/MS)
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for the quantification of vitamin D metabolites in clinical applications. Furthermore,
this technique has advantages compared to HPLC, which utilizes CO2 as supercritical
fluid; therefore, UPSFC –MS/MS is more cost-eﬀective than HPLC [79].
According to the literature, there are four columns widely used and tested
according to their resolution, selectivity, eﬃciency, and analysis time in order to
separate 25OHD3 from its epimer; these columns are COSMOSIL cholester
(stationary phase: cholester), Kinetex F5 (stationary phase: pentafluorophenyl),
Kinetex biphenyl (stationary phase: biphenyl), and COSMOSIL pentabromophenyl
(stationary phase: pentabromophenyl) [80]. Cholester columns do not separate epimers
of 25OHD3, while F5 and Biphenyl columns can separate the epimers. However, the
analysis time for biphenyl is longer than that of the F5 column. Also, the width of the
peak by biphenyl is larger. Pentabromophenyl, on the other hand, can separate the
epimers. Nonetheless, the analysis time for pentabromophenyl is longer than that for
the F5 column. Also, the width of the peak in pentabromophenyl is larger. COSMOSIL
pentabromophenyl could be improved if the particle size becomes smaller, as in F5,
subsequently reducing the time and improving the resolution and peak shape. Lastly,
the F5 column is the best column for separating 25OHD3 and its epimer [80].
According to Singh et al. [32], a longer 5-dinitrobenzoyl-(R)-phenylglycine column
(Chirex-PGLY and DNB 250 mm × 4.6 mm) gave good separation of the epimers of
25OHD. Unfortunately, the C3-epimer was not determined in all ages but only for
those less than one year old. Schleicher et al. [78] used ultra-performance liquid
chromatography–tandem mass spectrometry (UPLC–MS/MS) together with a
pentafluorophenyl (PFP) column to determine the epimers.
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1.9 Quality Assurance in Vitamin D Metabolites and C-3 Epimers
Determination
Recently, the International Vitamin D External Quality Assessment Scheme
(DEQAS) survey noted that liquid chromatography-tandem mass spectrometry (LC–
MS/MS), immunoassays, DBP-based assays, and HPLC are common assays that can
diﬀerentiate between 25OHD3 and its epimers. Around 14 methods were selected and
compared in this article. These methods are EIA (enzyme immunoassay), Abbott
Architect, chromatographic ligand binding assay, automated IDS (ImmunoDiagnostic
Systems), DiaSorin RIA (radioimmunoassay), DiaSorin Liason Total immunoassay,
DIA source immunoassay, HPLC, LC–MS/MS, IDS RIA, IDS-iSYS, IDS EIA, Roche
Total 25OHD, and Siemens ADVIA Centaur. Some of those methods can recognize
3-epi-25OHD3 among 25OHD3, including LC–MS/MS, HPLC, Roche Total 25OHD,
DIA source, and chromatographic ligand binding assay [24]. Gallo et al. [97]
determined that IDS-EIA and DiaSorin-RIA could be challenging to use for the
measurement of 25OHD3 because other vitamin D metabolites could interfere with 3epi-25OHD3 and 24,25(OH)2D3, which could lead to inaccurate measurements of
25OHD3. A recent study highlighted that the enzyme-linked immunosorbent assay (or
a commercial chemiluminescence vitamin D assay) and the LC–MS/MS method are
not equally able to evaluate vitamin D status in humans. This is because the majority
of commercial assay kits cannot distinguish between 25OHD and its epimer, which
leads to an overestimation of vitamin D levels as compared to LC–MS/MS, due to the
interfering epimers [18].
In order to improve the accuracy and separation of 25OHD measurements in
plasma, a Standard Reference Material (SRM) was developed by the National Institute
of Standards and Technology (NIST) in cooperation with the National Institutes of
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Health’s Oﬃce of Dietary Supplements (NIH-ODS). SRM 972 contains four diﬀerent
concentration levels of vitamin D serum samples, and each level has diﬀerent ratios of
vitamin D metabolites (25OHD3, 25OHD2, 3-epi-25OHD3). The standard
measurement for the SRM was carried out under three methods using isotope-dilution
(ID) mass spectrometry at the Centers for Disease Control and Prevention (CDC) and
the NIST [52]. The columns that were assessed in these measurements were C18 and
cyano columns, and it was observed that cyano is a better column than C18 for
resolving 25OHD3 and its epimers [52]. The Vitamin D External Quality Assessment
Scheme (DEQAS) also uses NIST standards to ensure the analytical reliability of
25OHD, 1,25(OH)2D, and 3-epi-25OHD3 assays [98]. These studies highlight the fact
that the epimers of vitamin D should be separated from the vitamin’s non-epimeric
components to properly determine circulating vitamin D levels in humans. This is
especially important if one has to analyze samples from pregnant women, newborns
under 1-year-old, and people with liver and kidney disorders. LC–MS/MS techniques
should be implemented in all the labs around the world, especially in Middle Eastern
countries where these techniques are non-existent. It is also very important that the
current methods in laboratories be standardized across the world to account for the
interference caused by epimers and isobars. This will help to accurately address the
epidemic caused by vitamin D deficiency.
1.10 Objectives of this Study
This study will give qualitative and quantitative information of vitamin D
metabolites in blood samples. Moreover, it will give an idea for clinical laboratories
about the importance of separation and differentiation between vitamin D metabolites
and their epimers. These epimers can overlap and interfere with 25OHD leading to
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overestimation and false-positive results during analysis in Immunoassay and
commercial chemiluminescence vitamin D assay method. The main aims of this study
are as follow: 1. To develop, validate and improve the UHPLC-MS/MS method that could
accurately detect and quantitate different metabolites of vitamin D and separate
the epimers and isobars.
2. To apply the developed and validated UHPLC-MS/MS method for accurate
measurement of blood vitamin D levels in obese Emirati population.
3. To determine if supplementation could increase either the level of major
vitamin D metabolites or their epimers or both in follow-up serum samples.
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Chapter 2: Materials and Methods
2.1 Materials
Materials, standards and other chemical solvents were purchased from various
companies.

Vitamin-D3,

25-hydroxyvitamin-D3

(25OHD3),

3-epi-25-

hydroxyvitamin-D3 (3-epi-25OHD3), 25-hydroxyvitamin-D2 (25OHD2), 3-epi-25hydroxyvitamin-D2 (3-epi-25OHD2), 1-α-25 dihydroxyvitamin-D3 (1α,25(OH)2D3),
1-α-25-dihydroxyvitamin-D2 (1α,25(OH)2D2), 25-hydroxyvitamin D3 (6, 19, 19-d3)
and Albumin from human serum were purchased from Green Oasis Medical
Equipment Installation and maintenance (Gomet) (Al-Ain, UAE), Vitamin-D2 and 7α-hydroxy-4-cholesten-3-one (7αC4) were obtained from LABCO LLC (Dubai,
UAE), hexane, LC-MS-grade water and LC-MS-grade methanol, ethyl acetate,
deionized water, formic acid, ammonium formate and phosphate buffered saline were
obtained from Emirates Scientific and Technical Supplies L.L.C. (ESTS) (Dubai,
UAE). Ascentis Express F5 column (dimensions: 150 mm × 2.1 mm × 2.7 μm) was
received from Gomet (Al-Ain, UAE).
2.2 Methods
2.2.1 Preparation of Standards Solution
The stock solutions of each vitamin D metabolite and internal standard (25hydroxyvitamin D3 (6, 19, 19-d3)) were prepared in methanol with a concentration of
1 mg/ml. All the stock solutions were kept and stored in amber vials at -80℃.
Furthermore, all the standards solutions of vitamin D metabolites should be kept in the
dark due to the fact that vitamin D metabolites are very sensitive to light; therefore,
they could be degraded. The working standards solution of vitamin D metabolites and
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internal standard were prepared by serial dilution of stock solutions in methanol to
desired concentrations.
2.2.2 Collection of Blood Samples
The blood samples of people were collected from 729 individuals, consisting of
277 baselines, which are vitamin D deficient volunteers, 277 follow-ups who are
supplemented volunteers, and 175 healthy volunteers. These individuals (baselines and
follow-ups) were 73 males (age range 18-82) and 204 females (age range 18-65), while
healthy volunteers were 8 males (age range 18-29) and 167 females (age range 18-65).
The serum of these blood samples was extracted after 15 minutes of centrifugation at
2200-2500 rpm. These serum samples were stored and kept at -80℃ in labeled plastic
amber vials until analysis.

The College of Medicine in the United Arab Emirates

University approved this recent Vitamin D study sample with the ethics approval
number (AAHEC-3-17-055).
2.2.3 Plasma Samples Extraction Method
The frozen human serum samples were taken from the refrigerator and thawed
at room temperature for around 20 minutes. After that, the serum samples were
vortexed, and 500 µl of each sample was transferred into a new test tube to begin a
liquid-liquid extraction. Afterward, 20 µl of working internal standard with a
concentration of 1 µg/ml was added to all calibrants, quality controls, and samples
except for the blank. The calibrants and quality controls of vitamin D metabolites
mixture were prepared in albumin from human serum (artificial serum), which
contained phosphate-buffered saline. All vitamin D metabolites and internal standard
in all calibrants, quality controls, and samples were extracted by adding 1.0 ml of
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hexane: ethyl acetate (9:1); then, this mixture was vortexed for a few seconds. After
that, this mixture was centrifuged at 4000 rpm for 20 minutes at standard conditions.
The mixture’s centrifugation leads to separate two layers: organic layer or supernatant
layer and aqueous layer; it is known that vitamin D is fat-soluble; therefore, it will be
extracted toward the organic layer. Pasteur pipettes were utilized to separate or transfer
the supernatant layer into a new amber glass vial. Then, further extraction was
performed once more to the remaining lower layer. All the extract layers from the
extraction processes were pooled together into a new amber vial. Afterward, the
extracts were dried at room temperature in a sample concentrator, which perform a
flow of air toward the extracts. Lastly, 100 µl of methanol: water (75:25, v/v) mixture
LC-MS/MS grade was added to re-suspend the residue and then transferred to LCMS/MS amber vial for the analysis by the instrument, as shown in Figure 4.
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Figure 4: Vitamin D extraction diagram. The diagram illustrates the Liquid-Liquid Extraction
method used to extract vitamin D metabolites and their epimers from human serum samples.
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2.2.4 Ultra-High-Pressure Liquid Chromatography-Tandem Mass
Spectrometry (UHPLC-MS/MS) System

The UHPLC-MS/MS system is composed of a Nexera Ultra High-Pressure
Liquid Chromatography (UHPLC) combined with Triple Quadrupole Mass
Spectrometer (Shimadzu, model 8060, Japan). The UHPLC (Nexera X2) system is an
advanced technology that provides an ultra-high-speed LC analysis. It consists of a
pump, auto-sampler, column oven, and degasser controlled by UHPLC-MS/MS
system. The UHPLC system has a higher-pressure tolerance, which enables using a
column with a small diameter and small particle size. Moreover, the auto-sampler part
has a high injection speed, and the system can use multi-solvents at the same time. The
Tandem Mass Spectrometer system consists of a triple quadrupole with a newly
developed UF-Qarray ion guide that increases the UHPLC-MS/MS sensitivity by
enhancing the ion signal’s intensity and reducing noise. UHPLC-MS/MS-8060 is a
highly sensitive instrument from Shimadzu company that provides a new level of
speed and responsiveness.
The separation of vitamin D metabolites and their epimers was achieved on a
reversed-phase analytical column Ascentis Express F5 column with a particle size 2.7
µm, an inner diameter of 2.1 mm, and a length of 150 mm. The analytical column was
connected with a guard column for increasing the life of the analytical column and
physical filtration. The injection volume for analysis into the UHPLC-MS/MS system
was 5 µl. After each sample injection, the sample contamination was minimized by a
wash program to rinse the needle with a methanol/water (75:25, v/v) mixture. The
column’s temperature was kept at 30℃, and the flow rate of the mobile phase was set
to 0.5 ml/min. Two mobile phases were used during analysis by the instrument: Mobile
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Phase A consisted of 5 mM ammonium formate and 0.1% formic acid in LC-MS grade
water, while Mobile Phase B consisted of 5 mM ammonium formate and 0.1% formic
acid in LC-MS grade methanol. The optimum chromatography of vitamin D
metabolites and their epimers was achieved by using a binary mobile phase gradient
pump which was set as follow: 75% of B and 25% of A were kept from 0:0 to 11:0
min, followed by increasing in B to 100% while decreasing in A to 0.0% at 15:00 min
that maintained for one minute. After that, mobile phase B was decreased to 75% while
mobile phase A was increased to 25% at 16:10 min and maintained until 20:00 min,
which is the end of the mobile phase gradient elution profile, as shown in Figure 5.

Mobile Phase Gradient
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Figure 5: Mobile phase gradient elution profile. A separation of vitamin D metabolites and
their epimers employs two mobile phases or solvents: Mobile Phase A contained 0.1% formic
acid or 5mM ammonium formate, and Mobile Phase B contained 0.1% formic acid or 5mM
ammonium formate. These two mobile phases differ significantly in polarity. Moreover, the
composition of solvents changes during the time analysis leads to the optimum
chromatography for vitamin D metabolites and their epimers.

A Tandem Mass Spectrometer system was managed using the positive
electrospray ionization (ESI) mode for all vitamin D metabolites and their epimers.
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Shimadzu’s Lab Solutions software was used to control the mass spectrometry
parameters. The software was also utilized to control UHPLC parameters (flow rate,
mobile phase gradient, injection volume, column’s temperature, and pump) and handle
or analyze the data, as shown in Table 2.
Table 2: UHPLC-MS/MS parameters and conditions. The table illustrates the factors and
conditions used to achieve an optimum chromatography for vitamin D metabolites and their
epimers.

UHPLC Parameters
Stationary Phase
Mobile Phase A
Mobile Phase B

UHPLC Conditions
Ascentis Express F5 column
(dimensions: 150 mm × 2.1 mm × 2.7 µm)
Water for LC-MS + 5mM ammonium formate +
0.1% formic acid
Methanol for LC-MS + 5mM ammonium formate +
0.1% formic acid

Injection Volume (µl)

5.00

Flow Rate (ml/min)

0.50

Column’s Temperature (℃)

30.00

Pump mode

Binary Gradient

MS Parameters

MS Conditions

Ion Source

Electrospray Ionization (ESI)

ESI Mode

Positive

Nebulizing gas ﬂow (L/min)

2.00

Drying gas flow (L/min)

8.00

Heating gas ﬂow (L/min)

8.00

Interface temp. (℃)

300.00

Heating block temp. (℃)

400.00

2.2.5 Method Development and Validation
U.S. Food and Drug Administration (FDA) suggested that the bioanalytical
method should be developed and validated by optimizing the conditions and
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procedures for the extraction and detection of the analyte and its metabolites.
Moreover, the bioanalytical parameters that are calibration curve, quality control
samples, specificity, sensitivity, accuracy, precision, recovery, linearity and stability
have to be involved in the method development and validation to ensure the method’s
suitability for the analysis of study samples [99, 100]. Three quality controls (QCs),
which are Quality Control High (QCH), Quality Control Medium (QCM), and Quality
Control Low (QCL), were used to determine linearity, stability, intra and inter-day
accuracy, intra and inter-day precision. The concentration for each QC level of some
vitamin D metabolites (vitamin D3, Vitamin D2, 25OHD and its epimer and 7αC4)
was 80 ng/ml, 40 ng/ml and 20 ng/ml for QCH, QCM, and QCL, respectively; while
each QC level for 1α,25(OH)2D was 0.8 ng/ml, 0.4 ng/ml and 0.2 ng/ml for QCH,
QCM, and QCL, respectively. Each QC level was prepared six times, along with the
calibration curve for each validation run. All calibrants and quality control samples
were prepared in a biological matrix (serum) that was a mixture of albumin from
human serum and phosphate-buffered saline at a concentration of 60 g/L.
The extraction efficiency was evaluated by determining the recovery’s
percentage. The recovery was implemented by preparing two sets of quality controls
where each set consisted of three levels of quality control (QCH, QCM, QCL) and
each level was prepared six times. In the first set, the quality control samples for QCH,
QCM, and QCL were spiked with methanol, then the internal standard was added to
all QC samples; however, in this set, the extraction method that is shown in Figure 4
was not performed; so, this set was called unextracted QC samples. In the second set,
the quality control samples for QCH, QCM, and QCL were spiked with blank serum,
then the internal standard was added to all QC samples; after that, the extraction
method was performed; therefore, this set was called extracted QC samples. The area
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under the normal peak in the chromatogram for the extracted QC samples was
compared with the unextracted QC samples; then, the recovery’s percentage was
calculated. The intactness of analyte (stability) was performed by preparing four sets
of quality controls in one day where each set consisted of three levels of quality control
(QCH, QCM, QCL) and each level was prepared six times. In all four sets, the quality
control samples for QCH, QCM, and QCL were spiked with blank serum; then, these
sets were stored at -20℃ except the first set where the internal standard was added to
all QC samples; then, the extraction method was performed. After 24 hr, the rest three
sets were taken out from the refrigerator and thawed at room temperature. In the second
set, the internal standard was added to all QC samples; then, the extraction method was
performed while the rest two sets were returned to the refrigerator and stored at -20℃.
After 24 hr, the rest two sets were taken out from the refrigerator and thawed at room
temperature. In the third set, the internal standard was added to all QC samples; then,
the extraction method was performed while the rest one set was returned to the
refrigerator and stored at -20℃. After 24 hr, the rest one set was taken out from the
refrigerator and thawed at room temperature. In the fourth set, the internal standard
was added to all QC samples; then, the extraction method was performed. Afterward,
the concentration results of QCs were compared between three freeze/thaw cycles at 0
hr, 24 hr, 48 hr, and 72 hr. The specificity experiment was operated by analyzing six
blank serum samples; then, each sample’s chromatogram was compared with other
samples to detect interferences (e.g., matrix components and impurities).
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Chapter 3: Results and Discussion
3.1 Chromatogram of Major Vitamin D Metabolites and Epimers with their
Respective Retention Times

The Ascentis Express F5 column under the optimum conditions, which were
controlled by the UHPLC part, provides a good separation of major vitamin D
metabolites and their epimers and isobars with a normal peak shape, as shown in
Figure 7. It can be noticed that the method can separate the major vitamin D
metabolites from their epimers and isobar, which are 3-epi-25OHD (epimer) and 7αC4
(isobar). Although the major vitamin D metabolites and their epimers have similar
structure and mass, there is a difference in retention time between them, as shown in
Table 3. When the tandem mass spectrometry (MS/MS) is used by itself to analyze
25OHD and its epimer and isobar, the mass of 25OHD overlaps with its epimer and
isobar, which leads to false-positive results. For instance, under or overestimation of
actual 25OHD concentration occurred due to co-elution and sharing the exact mass
with its epimer and isobar. If the epimers of 25OHD and its isobar have the same
precursor to product ion transition or Multiple Reaction Monitoring (MRM), it will be
difficult for tandem mass spectrometry by itself to distinguish between co-eluting
metabolites for accurate estimation of 25OHD, as shown in Figure 6. Therefore, the
UHPLC part with MS/MS part provides a powerful combination for bioanalytical
analysis.
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Figure 6: Overestimation of 25OHD3 with its epimer and isobar by mass spectrometry
analysis.

According to Figure 7, the universally measured vitamin D metabolites
(25OHD3 and 25OHD2) have been separated from their epimers. In this case, the
UHPLC-MS/MS instrument has solved the limitations of two techniques, which are
Immunoassay and mass spectrometry. These limitations have been resolved by
chromatographic separation of 25OHD2 and 25OHD3 and their epimers based on their
polarities using the reverse phase column, Ascentis Express F5 column (dimensions:
150 mm × 2.1 mm × 2.7 µm). Furthermore, although 25OHD2 and 3-epi-25OHD3
have almost the same retention time, their ionization behaviors are different.
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Figure 7: A representative chromatogram of vitamin D metabolites with epimers and isobar.
The vitamin D metabolites with epimers and isobar have been separated by UHPLC-MS/MS
instrument.

According to Table 3, although D3 and D2 have almost similar retention time
and polarities, their masses are different, leading to separate them based on mass to
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charge (m/z) ratios. 25OHD and its epimer have the same mass to charge (m/z) ratios;
however, their polarities are slightly different that can be separated in the UHPLC part
using a reverse-phase column. Although 25OHD3, 3-epi-25OHD3, and 7αC4 have the
same masses, their retention times differ. Figure 7 and Table 3 illustrate that the
UHPLC-MS/MS separates the vitamin D metabolites and their epimers based on mass
to charge (m/z) ratios and polarities.
Table 3: The names, structures, and masses of vitamin D metabolites and epimers with their
respective retention times. Although some metabolites have similar structure and mass, the
retention time of each metabolite is different.

Name

Vitamer Structure

Cholecalciferol
(Vitamin D3)

Mass
(g/mol)

Retention
Time
(min)

384.64

15.104

396.65

15.072

400.64
382.62
(-H2O)

6.008

C27H44O

Ergocalciferol
(Vitamin D2)

C28H44O
25-Hydroxyvitamin
D3
(25OHD3)

C27H44O2
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Table 3: The names, structures, and masses of vitamin D metabolites and epimers with their
respective retention times. Although some metabolites have similar structure and mass, the
retention time of each metabolite is different (cont’d).

Name

Vitamer Structure

3-epi-25Hydroxyvitamin
D3
(3-epi-25OHD3)

Mass
(g/mol)

Retention
Time
(min)

400.64
382.62
(-H2O)

6.552

412.65
394.63
(-H2O)

6.682

C27H44O2

25-Hydroxyvitamin
D2
(25OHD2)

C28H44O2
3-epi-25Hydroxyvitamin
D2
(3-epi-25OHD2)

412.65
394.63
(-H2O)

7.257

C28H44O2

1α,25Dihydroxyvitamin
D3
(1α,25(OH)2D3)

416.64
398.62
(-H2O)

3.108

C27H44O3

1α,25Dihydroxyvitamin
D2
(1α,25(OH)2D2)

428.65
410.63
(-H2O)
C28H44O3

3.452
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Table 3: The names, structures, and masses of vitamin D metabolites and epimers with their
respective retention times. Although some metabolites have similar structure and mass, the
retention time of each metabolite is different (cont’d).

Name

Vitamer Structure

7α-Hydroxy-4cholesten-3-one
(7αC4)

Mass
(g/mol)

400.64

Retention
Time
(min)

13.763

C27H44O2

25Hydroxyvitamin
D3 (6,19,19-d3)

403.66
385.64
(-H2O)

5.983

C27D3H41O2
3.2 Determination of Method Validation Parameters
The method validation parameters, which are intra and inter-day precision, intra
and inter-day accuracy, recovery, linearity, specificity, and stability, were calculated
by analyzing six QC samples at three different concentration levels (QCL, QCM, and
QCH). The QCs values were used to calculate the percent of intra and inter-day
precision using the following equation:

%CV =

(𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛)
(𝑚𝑒𝑎𝑛)

𝑥 100

The percent of intra and inter-day accuracy was calculated using the following
equation:

%Accuracy =

(𝑚𝑒𝑎𝑛 𝑣𝑎𝑙𝑢𝑒)
(𝑛𝑜𝑚𝑖𝑛𝑎𝑙 𝑣𝑎𝑙𝑢𝑒)

𝑥 100
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The extracted and unextracted QCs values were used to calculate the percent of
absolute recovery using the following equation:

%Recovery =

(𝑚𝑒𝑎𝑛 𝑒𝑥𝑡𝑟𝑎𝑐𝑡𝑒𝑑 𝑄𝐶 𝑣𝑎𝑙𝑢𝑒𝑠)
(𝑚𝑒𝑎𝑛 𝑢𝑛𝑒𝑥𝑡𝑟𝑎𝑐𝑡𝑒𝑑 𝑄𝐶 𝑣𝑎𝑙𝑢𝑒𝑠)

𝑥 100

The instrument’s sensitivity toward vitamin D metabolites was measured using the
Lower Limit of Detection (LOD). The LOD was determined by comparing the peak’s
intensity for the lowest concentration of the analyte to the chromatogram’s noise level.
The lowest concentration of an analyte should give response higher three times than
the background or noise level. The linear range of some vitamin D metabolites was
0.5-100 ng/ml while for 1α,25(OH)2D was 0.015 – 1 ng/ml with a very good regression
value (linearity), as shown in Table 4.
The method validation parameters were found in an acceptable range for each
QC level. For example, the percentage of the coefficient of variations and accuracy
indicates that the method used to analyze vitamin D metabolites and their epimers has
good precision and accuracy for intra and inter-day. Moreover, the method illustrates
a good recovery percentage, which explains that the extraction method is efficient in
extracting vitamin D metabolites and epimers from serum samples, as shown in Table
4. Various studies were reported different LOD and LOQ values. For instance, Mϋller
et al. [101] reported the LOQ for 25OHD3 and its epimer of 0.1 and 1.0 ng/ml,
respectively. Moreover, according to Ronda et al. [102] , the LOD for 25OHD3 and
its epimer was 0.68 and 0.76 ng/ml, while LOQ was 1.36 and 1.52 ng/ml, respectively,
by using LC-MS/MS 6490. Also, the LOD and LOQ were reported for 25OHD3 and
its epimer by using LC-MS/MS 6410; the LOD was 0.8 ng/ml while LOQ was 1.4
ng/ml for both metabolites. Another study reported the LOD and LOQ values; for
instance, the LOD for 25OHD3 and its epimer was 0.075 and 0.09 ng/ml while LOQ
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was 0.25 and 0.3, respectively [94]. Table 4 shows the values of LOD and LOQ for
nine metabolites of vitamin D by UHPLC-MS/MS 8060, which explains that the
method is extremely sensitive. Moreover, it illustrates the percent of intra and interday precision and accuracy results among six quality control samples for each quality
control level. Furthermore, the values of percentage recovery were calculated by
comparing areas under the normal curve in the chromatogram for the extracted and
unextracted quality control samples. A Low Limit of Detection (LOD) was determined
from the lowest concentration of vitamin D metabolite that can be detected by the
instrument.

Table 4: The values of method validation parameters for each quality control level.
Intra-day
N

Vitamin D
metabolites

1

Vitamin D3

2

Vitamin D2

3

25OHD3

4

3-epi-25OHD3

5

25OHD2

6

3-epi-25OHD2

7

1α,25(OH)2D3

8

1α,25(OH)2D2

9

7αC4

Conc.
(ng/ml)
QCH 80
QCM 40
QCL 20
QCH 80
QCM 40
QCL 20
QCH 80
QCM 40
QCL 20
QCH 80
QCM 40
QCL 20
QCH 80
QCM 40
QCL 20
QCH 80
QCM 40
QCL 20
QCH 0.8
QCM 0.4
QCL 0.2
QCH 0.8
QCM 0.4
QCL 0.2
QCH 80
QCM 40
QCL 20

Inter-day

Precision
(%CV)

%
Accuracy

Precision
(%CV)

%
Accuracy

1.31
2.86
4.13
9.4
11.3
6.3
3.5
2.7
6.1
3.3
3.1
3.5
3.3
2.7
2.8
3.2
4.9
7.1
3.6
4.2
4.4
3.9
4.4
3.2
4.1
2.3
3.2

98.9
99.4
87.1
89.4
97.5
99.2
99.1
97.3
99.9
89.1
87.3
89.2
88.7
99.9
99.8
89.9
84.6
85.8
99.7
86.4
89.2
99.9
99.4
98.9
79.9
88.6
98.3

2.89
2.33
5.32
9.6
13.3
11.3
2.9
3.7
7.4
8.9
10.9
4.3
3.8
3.9
3.4
2.2
2.7
3.5
2.6
4.4
5.6
4.3
6.3
5.2
3.1
3.1
5.4

90.2
89.4
89.8
89.3
94.8
93.2
99.2
99.8
98.1
99.9
87.6
98.5
89.3
98.9
101.2
88.3
87.1
88.5
88.9
87.3
88.5
87.8
98.9
89.8
88.1
85.3
86.2

%
Recovery
77
75
98
88
89.3
105
86
89
111
80
96
86
82
99
115
86.5
97
89
88
82
97
86
87
89.1
92.45
97
92

LOD
(ng/ml)

LOQ
(ng/ml)

Linearity

Linear
Range
(ng/ml)

0.05

0.5

0.998

0.5 - 100

0.05

0.5

0.997

0.5 - 100

0.025

0.5

0.998

0.5 - 100

0.05

0.5

0.998

0.5 - 100

0.025

0.5

0.998

0.5 - 100

0.05

0.5

0.998

0.5 - 100

0.01

0.015

0.997

0.015 - 1

0.01

0.015

0.993

0.015 - 1

0.1

0.5

0.999

0.5 - 100
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The analysis of six blank serum samples determined the specificity of the
method. For instance, six blank serums were prepared without vitamin D metabolites;
then, the blank serums were analyzed by UHPLC-MS/MS instrument. After that, the
chromatogram for each blank serum was compared and overlaid with other blank’s
chromatograms in order to reveal any co-eluting or interfering peaks, which could have
the same retention time as the vitamin D metabolites. It was found that there are no
interfering or co-eluting peaks generated from any interferences in the serum. There
was only a noise level without any strange peaks, which could interfere with the
vitamin D peak and lead to overestimating the result, as shown in Figure 8.

Figure 8: Overlaid chromatograms of six blank serum samples. The specificity experiment
results illustrate that the interfering or co-eluting peaks did not exist at the respective retention
times of vitamin D metabolites.

The stability of the vitamin D metabolites and their epimers was assessed by
analyzing six QC samples of each concentration level (QCH, QCM, and QCL). The
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QC samples were analyzed over 24 hr, 48 hr, and 72 hr (three sequential freeze/thaw
cycles); then, the results were compared between each other and with time zero. Figure
9 shows the percentage change in the intactness of vitamin D metabolites and their
epimers over three freezes/thaw cycles. The vitamin D3 exhibited more than 30%
change in 24 hr, while for 48 hr and 72 hr, the percentage change was around 20. The
stability of vitamin D2 was almost the same as vitamin D3. The 25OHD3 illustrated a
higher percentage change in 24 hr compared to 48 hr and 72 hr, while its epimer was
around 20% of all three freezes/thaw cycles. The highest percent of change was
observed by 3-epi-25OHD2 in 48 hr and 72 hr compared to all vitamin D metabolites.
The rest of the metabolites (25OHD2, 1α,25(OH)2D3, 1α,25(OH)2D2, and 7αC4) have
fluctuated around 20%. Ultimately, the results of stability or intactness of vitamin D
metabolites and their epimers revealed that these metabolites are not very stable with
consecutive cycles of freezing and thawing.

Figure 9: Vitamin D metabolites stability over three consecutive freeze/thaw cycles (24 hr, 48 hr, 72 hr). The Quality Control High (QCH), Quality Control
Medium (QCM), and Quality Control Low (QCL) are represented by blue, orange, and grey bars at 24 hr, 48 hr, and 72 hr intervals, respectively. The values
of six quality control samples for each level (QCH, QCM, and QCL) were used to estimate the stability of each vitamin D metabolite over three consecutive
freeze/thaw cycles. The range of % change in vitamin D metabolites stability was between 0 and 60.

46

47
3.3 Identification of Precursor and Product Ions (Multiple Reaction Monitoring,
MRM) for Vitamin D Metabolites and their Epimers

The precursor to product ion transition and collision energy of the epimers were
the same as 25OHD3 and 25OHD2; therefore, the tandem mass spectrometry by itself
cannot differentiate between 25OHD and its epimer, which lead to cause
overestimation of 25OHD and give false-positive results. The remaining metabolites
of vitamin D revealed different MRM and collision energies, as shown in Table 5. An
accurate and highly sensitive UHPLC-MS/MS-8060 instrument facilitates the
determination of vitamin D metabolites and epimers accurately during the analysis
time.

Mass spectrometry analysis was operated on the MS/MS-8060 (Triple

Quadrupole Mass Spectrometer) system in positive electrospray ionization (ESI+)
mode for all vitamin D metabolites and epimers due to that the instrument was highly
sensitive when the vitamin D metabolites are positively charged. The precursor ions
of 25OHD and its epimer, 1α,25(OH)2D3, 1α,25(OH)2D2, and 25OHD3 (6, 19, 19-d3)
metabolites were most sensitive when these metabolites lose water molecule with
simultaneous production of [M+H-H2O]+. Moreover, the MRM mode gives the most
sensitive product ions. The 25OHD3, 3-epi-25OHD3 (epimer), 7αC4 (isobar) have the
same masses without losing water molecules. These factors lead to under- and overestimation of 25OHD and give false-positive results; therefore, the separation of these
coeluting interfering components is crucial for accurate measurement of vitamin D.
Table 5 illustrates the selected MRM transitions along with their collision energies.
Lastly, the developed and validated method for the analysis of vitamin D
metabolites and epimers revealed that UHPLC-MS/MS technique was accurate,
reproducible, specific, quick, reliable, and robust. Furthermore, the method can
distinguish between major metabolites of vitamin D and their epimers and isobars;
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therefore, the method will be more reliable for the quantitative and qualitative analysis
of vitamin D in human serum samples.
Table 5: The names of the analytes, masses, precursor and product ions along with their
collision energies. Some vitamin D metabolites have the same MRM and collision energies.

No.

Analytes

Mass
(g/mol)

1

Vitamin D3

384.64

2

Vitamin D2

396.65
400.64
382.62
(-H2O)
400.64
382.62
(-H2O)
412.65
394.63
(-H2O)
412.65
394.63
(-H2O)
416.64
398.62
(-H2O)
428.65
410.63
(-H2O)

3

25OHD3

4

3-epi-25OHD3

5

25OHD2

6

3-epi-25OHD2

7

1α,25(OH)2D3

8

1α,25(OH)2D2

9

7αC4

400.64

10

25OHD3(6,19,19d3)

403.66
385.64
(-H2O)

Precursor
(m/z)
385
385
385
397.1
397.1

Product
(m/z)
367
259
91
379.4
69

Collision
energy (eV)
-13
-16
-55
-17
-29

383.2
383.2

365.3
107.1

-15
-30

383.2
383.2

365.3
107.1

-15
-30

395.1
395.1

377.3
81.1

-17
-38

395.1
395.1

377.3
81.1

-17
-38

399.1

381.3

-14

411.1
411.1

135.3
133.1

-13
-12

401.55
401.55
401.55
386.35
386.35
386.35

383.25
97.1
177.2
368.25
257.2
95.2

-16
-29
-23
-15
-183
-35

3.4 Analysis of Human Serum Samples (Baseline, Follow-up and Healthy)
In many clinical laboratories, the 25OHD is considered the best metabolite of
vitamin D to determine the vitamin D status in human blood samples. Measurement
of total 25OHD is defined as vitamin D status; total 25OHD refers to 25OHD3 and
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25OHD2 with their epimers. The measurement of 1α,25(OH)2D metabolite is more
complicated than 25OHD for several reasons: the short half-life of 1α,25(OH)2D,
which is between 4 – 15 hr compared to its parent 25OHD, which is between 21 – 30
days, instability of 1α,25(OH)2D and presence at a low concentration within the
circulation (picomolar concentration) [103, 104]. Different organizations proposed the
reference values of vitamin D; therefore, the normal level of vitamin D in the blood
may differ slightly between these organizations. For instance, the optimum level of
25OHD, 20 ng/ml, was proposed by the institute of medicine, while the vitamin D
council considered the optimum level between 40 and 80 ng/ml [36, 105]. One of the
guidelines mentioned the reference value of total 25OHD and 1α,25(OH)2D in the
blood. For example, the optimum levels of total 25OHD are between 25 and 80 ng/ml
while the optimum range of 1α,25(OH)2D in males and females is 18 – 64 pg/ml and
18 – 78 pg/ml, respectively [106]. Table 6 illustrates the normal range of 25OHD levels
in serum that was proposed by different studies. The vitamin D results of male and
female patients are illustrated separately in Figures 10 and 11.
Table 6: The normal range of vitamin D in serum proposed in various studies.

Study
[107]
[13]
[108]
[109]
[110]
[111]

Deficient
(ng/ml)
<10
<12
<20
<10
<20
<10

Insufficient
(ng/ml)
10 - 20
12 - 20
21 - 29
10 - 30
21 - 29
10 - 30

normal
(ng/ml)
20 - 30
20 - 50
30 - 100
30 - 80
30 - 60
30 - 100

Excess
(ng/ml)
>200
>50
>100
>100
>150
>100

Different guidelines have been published by various studies about serum
vitamin D levels for good health; therefore, it seems that there is no consensus about
an adequate level of vitamin D [13, 107-111], as shown in Table 6.
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The concentration of vitamin D metabolites is deficient in the baseline patients.
When vitamin D deficient volunteers (baseline samples) take vitamin D supplements,
the levels of vitamin D metabolites have been increased (follow-up samples), as shown
in Figures 10 and 11. Although the levels of vitamin D metabolites in follow-up
samples have increased, most of them were still lower than the normal range proposed
by the studies, Table 6. 3-epi-25OHD2 concentration was not detected. The vitamin
D3 concentration in the follow-up samples of both males and females is high;
therefore, either 25OHD3 or its epimer should be increased significantly when vitamin
D3 is converted to 25OHD3 by CYP2R1 enzyme in the liver (Chapter 1). On the other
hand, this study shows that 25OHD3 is increased slightly in the follow-up samples
because vitamin D3 could probably be converted to other forms. For example, a few
new vitamin D metabolites such as 20, 22(OH)2D3, and 22OHD3 could be produced
in epidermal keratinocytes upon hydroxylation of vitamin D3 by CYP11A1 enzyme
[64-66]. Moreover, UVB light may activate the CYP11A1 enzyme; thus, it will lead
to a decrease in the vitamin D3 substrate availability for classical hydroxylation to
form 25OHD3 and its epimer [31].
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Male
95

85

75

Concentration (ng/ml)

65

55

45

35

25

15

5

-5

Baseline

Follow-up

Healthy

Figure 10: A comparison between vitamin D metabolites concentration in male blood samples.
3-epi-25OHD2 concentration was not detected in baseline samples while 1α,25(OH)2D was
not detected in the baseline, follow-up, and healthy samples. The standard errors of the mean
were represented by the error bars in the graph.
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85
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Concentration (ng/ml)

65

55
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35
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5
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Figure 11: A comparison between vitamin D metabolites concentration in female blood
samples. 3-epi-25OHD2 concentration was not detected in baseline samples while
1α,25(OH)2D was not detected in the baseline, follow-up and healthy samples. The standard
errors of the mean were represented by the error bars in the graph.

The UHPLC-MS/MS method can separate and distinguish the epimers and
isobars of vitamin D, which caused an interference during the analysis of the major
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forms of vitamin D in human blood samples; therefore, this method leads to giving an
actual result due to its ability to measure and distinguish the major metabolites of
vitamin D (25OHD3 and 25OHD2) accurately without combining the epimers with
these major metabolites. Table 7 illustrates the results of vitamin D metabolites in
baseline, follow-up, and healthy samples of mixed gender volunteers (male + female).
When the vitamin D deficient volunteers (baseline) were supplemented, the
levels of all vitamin D metabolites and epimers were increased; however, the increase
was not sufficient to achieve the normal range proposed by the studies (Table 6), as
shown in Table 7. Although the vitamin D3 was increased significantly in follow-up
samples, the levels of other vitamin D3 metabolites and epimers were not increased
sufficiently, which may explain that vitamin D3 was being converted not only to major
form (25OHD3) but also to other forms such as 20, 22(OH)2D3, and 22OHD3 [64-66].
Probably, this can be resolved by increasing the dietary vitamin D intake to achieve
the normal range proposed by the studies (Table 6).
According to Table 7, if the components of total 25OHD (25OHD3 + 3-epi25OHD3 + 25OHD2 + 3-epi-25OHD2) are combined together in the follow-up and
healthy samples, the total 25OHD will be in the sufficient range according to the
studies (Table 6). Moreover, the total 25OHD for follow-up and healthy samples is in
the normal range (25 – 80 ng/ml) according to Mosby’s Diagnostic and Laboratory
Test Reference [106]. The immunoassay technique will consider 25OHD3, 3-epi25OHD3, 25OHD2, and 3-epi-25OHD2 as one entity; so, it will combine the
components of total 25OHD and overestimate the results.
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Table 7: A comparison between the average concentrations of vitamin D metabolites and
epimers for baseline, follow-up and healthy mixed-gender volunteers. The last column shows
the average concentrations in ng/ml and the standard deviation (SD). The symbol N represents
the total number of analyzed samples of baseline, follow-up, and healthy volunteers. 3-epi25OHD2, 1α,25(OH)2D3 and 1α,25(OH)2D2 were not detected.

No.

Analytes

1

Vitamin D3

2

Vitamin D2

3

25OHD3

4

3-epi-25OHD3

5

25OHD2

6

3-epi-25OHD2

7

1α,25(OH)2D3

8

1α,25(OH)2D2

9

7αC4

Sample Type

N

Mean ± SD

Base line
Follow-up
Healthy
Base line
Follow-up
Healthy
Base line
Follow-up
Healthy
Base line
Follow-up
Healthy
Base line
Follow-up
Healthy
Base line
Follow-up
Healthy
Base line
Follow-up
Healthy
Base line
Follow-up
Healthy
Base line
Follow-up
Healthy

277
277
175
277
277
175
277
277
175
277
277
175
277
277
175
277
277
175
277
277
175
277
277
175
277
277
175

25.03 ± 12.40
81.09 ± 56.31
25.07 ± 21.96
11.68 ± 2.33
14.34 ± 3.84
11.88 ± 2.79
7.89 ± 2.65
14.76 ± 7.65
12.56 ± 3.84
2.60 ± 0.48
3.85 ± 2.10
6.26 ± 1.19
9.25 ± 4.52
11.73 ± 6.94
18.18 ± 9.58
n.d.
8.13 ± 2.94
5.88 ± 0.22
n.d.
n.d.
n.d.
n.d.
n.d.
n.d.
23.88 ± 22.94
26.27 ± 20.75
40.36 ± 31.84

Figure 12 illustrates that the epimers and isobars of 25OHD3 account for a
significant proportion, which will lead to an overestimation of actual 25OHD3
concentrations due to co-elution and sharing the exact mass with its epimers (3-epi25OHD3) and isobars (7αC4). According to the guidelines proposed by some studies
(Table 6), when the epimers and isobars are excluded from the universally measured
25OHD, the baseline, follow-up, and healthy volunteers are considered deficient
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25OHD3 and 25OHD2; as shown in Figure 13. In contrast, follow-up and healthy
volunteers are considered insufficient according to the guidelines of other studies
(Table 6). The UHPLC-MS/MS method excludes and differentiates the epimers and
isobars that cause an interference leading to overestimate an actual concentration of
major vitamin D metabolites (25OHD3 and 25OHD2) and gave false-positive results;
as shown in Figure 12. In the immunoassay technique, 25OHD3 and 25OHD2 with
their epimers are considered one entity; according to Figure 12, when 25OHD3 and
25OHD2 with their epimers are combined, the baseline samples are in an insufficient
range while follow-up samples are in a normal range. Healthy volunteers are in the
normal range of vitamin D when the epimers are accounted. Interestingly, the 25OHD3
and 25OHD2 concentrations, which were around 12.56 ng/ml and 18.18 ng/ml,
respectively, in the healthy volunteers were even less than the adequate value proposed
by different studies (Table 6); as shown in Figure 13, probably, the vitamin D is diluted
in an immense volume of obese volunteers. In the mass spectrometry technique,
25OHD3, 3-epi-25OHD3, and 7αC4 have the same masses; therefore, they are
recognized as one entity. In Figure 12, if 25OHD3, 3-epi-25OHD3, and 7αC4 are
gathered, the baseline, follow-up, and healthy samples will be in the sufficient range;
therefore, the results will be overestimated. This study displays that UHPLC-MS/MS
technique erases and excludes the epimers and isobar interferences; accordingly, it can
separate epimers and isobar from major vitamin D metabolites based on their mass to
charge ratios (m/z) and polarities, leading to give actual results.
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Concentration (ng/ml)
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60
50
40
30
20
10
0
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3-epi-25OHD3

25OHD2
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3-epi-25OHD2

7αC4

Figure 12: The bar chart illustrates a comparison of major vitamin D metabolites and their
epimers and isobars at the baseline, follow-up, and healthy mixed-gender samples. The stacked
columns show the combination between major forms of vitamin D (25OHD3 + 25OHD2)
along with the co-eluting epimers (3-epi-25OHD3 + 3-epi-25OHD3) and the isobar (7αC4).
The standard errors of the mean were represented by the error bars in the graph.

35
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Concentration (ng/ml)

25
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25OHD2

Figure 13: The bar chart illustrates a comparison of major vitamin D metabolites (25OHD3 +
25OHD2) at the baseline, follow-up, and healthy mixed-gender samples. The stacked columns
show the combination of these major forms. The standard errors of the mean were represented
by the error bars in the graph.
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Chapter 4: Conclusion

The Immunoassay technique is one of the first techniques used in measuring
vitamin D. It is widely used in clinical laboratories; however, it has many limitations.
One of the main challenges that face this technique is the low specificity to assess
vitamin D metabolites. For example, this technique measures total 25OHD and
1α,25(OH)2D concentrations because it measures D2 and D3 as one entity and cannot
distinguish between them [85]; therefore, this technique is not in agreement with the
US Food and Drug Administration (FDA), which stipulates that 25OHD3 and
25OHD2 should be detected in 25OHD assays [112].
High-Performance Liquid Chromatography (HPLC) was considered until lately
as the standard technique for quantifying vitamin D [83, 113]. HPLC was preferred in
terms of accuracy and precision more than Immunoassay. It was able to solve the
problem of separating 25OHD2 and 25OHD3 levels. Another advantage for HPLC
and LCMS is that they can extract 25OHD and remove the binding protein by either
liquid-liquid extraction or solid-phase extraction. The HPLC method has limitations
as well; for example, it requires large sample volumes and has less sensitivity for low
levels of vitamin D metabolites compared to LC-MS/MS [114].
The best available technique to quantify and distinguish between 25OHD3 and
25OHD2, along with their epimers, is the LC-MS/MS. It can eliminate most technical
problems of HPLC and immunoassays methods. What gives LC-MS/MS preference is
the high specificity and sensitivity of it. LC-MS/MS has superior selectivity compared
to the other methods due to its ability to differentiate between different metabolites via
chromatographic separation and mass transition differences. The compounds that have
differences in polarities and mass to charge (m/z) ratios can be separated by LC-
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MS/MS method; moreover, this method has very Low Limits of Quantitation (LOQ),
which gives a higher sensitivity. LC-MS/MS is the main technique for quantification
of vitamin D metabolites in clinics due to its accuracy and precision [115].
Epimers are compounds that have different arrangements around a carbon atom
with the same chemical formula. The epimerization pathway of vitamin D occurs at
C-3 during the standard metabolic pathway [24]. The separation of epimers and isobars
from effective forms of vitamin D metabolites is crucial because epimers peaks can
interfere with the standard peaks for major metabolites, which affect the measurement
of the actual concentrations of vitamin D. 3-epi-25OHD3 is the most common epimer.
Two main compounds can affect the analysis of the universally measured 25OHD and
interfere with it as isobars. These compounds are 1α-hydroxyvitamin D3(1αOHD3,
exogenous pharmaceutical compound) and 7-α-hydroxy-4-cholesten-3-one (7αC4,
endogenous bile acid precursor) [35]. In this study, when the total 25OHD
concentration is measured in the blood, the epimers and isobars of 25OHD contribute
to a significant proportion of total 25OHD; subsequently, they will lead to an
overestimation of actual levels of 25OHD; as shown in Figure 12.
Most of the existing methods of vitamin D analysis can lead to an
overestimation of vitamin D levels due to interfering epimers, especially among infant
groups and pregnant women. The determination of vitamin D metabolites and vitamin
D epimers is not very reliable due to cross-reactivity issues. Studies have shown that
LC–MS/MS is the gold standard method to quantify and separate epimers, bypassing
the issues caused by their interference. All major vitamin D metabolites can be
epimerized at the C3 position. It is known that very few labs in the world account for
misleading measures due to overlapping C3-epimers. It is also known that routine
vitamin D blood tests for healthy adults will not be significantly aﬀected by epimeric
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interference using LC–MS/MS assays. Recent genetic models also show that the
genetic determinants and potential factors of C3-epimers diﬀer from those of non-C3epimers.
Moreover, mice have higher epimer concentrations than humans, and the
epimerization process for mice with orally ingested vitamin D3 is higher than that for
mice irradiated by UVB light. It was established that oral supplementation of vitamin
D could cause increased production of epimers in mice but not in humans. Under
clinical laboratory conditions, time and throughput are essential concerns. For
example, separating isomers by chromatographic analysis using HPLC, LC–MS, and
LC–MS/MS is time-consuming and utilizing chiral or CN columns could lead to
compromised throughput. However, PFP columns could be more suitable. The
biological origin of these epimers has not yet been clearly identified, and more clinical
research is required [24, 31, 63, 73, 76-78, 116, 117]. The C3-epimers of vitamin D
may well have an important role to play in clinical research, and more research is
warranted. Finally, the method used in our study could be useful to study vitamin D
metabolites and their epimers in hair samples; also, it could be useful to study the
relationship between vitamin D and other diseases such as Covid-19.
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